In Vitro Activity of LY333328 Against Vancomycin-Resistant Enterococci,Methicillin-Resistant Staphylococcus aureus,and Penicillin-Resistant Streptococcus pneumoniae |
| |
| Institution: | 1. P.G. Department of Biotechnology, Utkal University, Bhubaneswar 751004, Odisha, India;2. P.G. Department of Zoology, North Orissa University, Baripada, 757003 Mayurbhanj, Odisha, India;1. Department of Microbiology, Jagiellonian University Medical College, Krakow, Poland;2. Institute of Dentistry, Department of Dental Prophylaxis and Experimental Dentistry, Jagiellonian University Medical College, Krakow, Poland;3. Department of Microbiology, Analytical and Microbiological Laboratory of Ruda Slaska, KORLAB NZOZ, Ruda Slaska, Poland;4. Higher School of Medicine in Sosnowiec, Poland;1. JMI Laboratories, North Liberty, Iowa, USA;2. University of Iowa College of Medicine, Iowa City, Iowa, USA |
| |
| Abstract: | We report the activity of LY333328 against 35 clinical isolates of vancomycin-resistant enterococci (including organisms carrying the vanA, vanB, vanC-1, and vanC-2/3 genes, as determined by PCR), 33 clinical isolates of methicillin-resistant S. aureus, and 29 clinical isolates of high-level penicillin-resistant S. pneumoniae. All isolates of vancomycin-resistant enterococci were inhibited by 2 μg/mL LY333328, and 8 μg/mL LY333328 was bactericidal against all isolates tested. All isolates of methicillin-resistant S. aureus were inhibited by 1 μg/mL LY333328, and 4 μg/mL LY333328 was bactericidal against all methicillin-resistant S. aureus isolates tested. All isolates of penicillin-resistant S. pneumoniae were inhibited by <0.125 μg/mL LY333328, and 0.25 μg/mL LY333328 was bactericidal against all S. pneumoniae isolates tested. LY333328 is a promising new glycopeptide antimicrobial agent. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
